Profile data is unavailable for this security.
About the company
hVIVO plc is a United Kingdom-based specialist early-stage drug development contract research organization (CRO) and human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base. It specializes in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its quarantine facility. The Company also offers comprehensive virology and immunology laboratory services under the hLAB brand. The Company, through its subsidiary, operates an approximately 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. It also offers Early Drug Development Consulting and Biometry services to the biopharma sector. The Company also provides industry-standard, temperature-controlled storage solutions for biological and clinical materials.
- Revenue in GBP (TTM)51.28m
- Net income in GBP5.28m
- Incorporated2011
- Employees301.00
- LocationhVIVO PLC40 Bank Street, Floor 24LONDON E14 5NRUnited KingdomGBR
- Phone+44 20 7756 1300
- Websitehttps://hvivo.com/
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| IXICO PLC | 6.53m | -1.65m |
| Genflow Biosciences PLC | 0.00 | -1.80m |
| Solvonis Therapeutics PLC | 0.00 | -2.60m |
| Fusion Antibodies PLC | 1.60m | -1.47m |
| Sareum Holdings Plc | 0.00 | -4.44m |
| Arecor Therapeutics PLC | 5.06m | -8.10m |
| Poolbeg Pharma PLC | 0.00 | -5.71m |
| ImmuPharma PLC | 0.00 | -3.93m |
| hVIVO PLC | 51.28m | 5.28m |
| Skinbiotherapeutics PLC | 4.64m | -696.25k |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -7.81m |
Institutional shareholders
| Holder | Shares | % Held |
|---|---|---|
| Octopus Investments Ltd.as of 24 Oct 2025 | 94.91m | 13.81% |
| Rathbones Investment Management Ltd.as of 05 Nov 2025 | 75.50m | 10.99% |
| Investec Wealth & Investment Ltd.as of 30 Jun 2025 | 49.76m | 7.24% |
| Canaccord Genuity Wealth Ltd.as of 28 Feb 2025 | 4.75m | 0.69% |
| Barclays Investment Solutions Ltd.as of 28 Jan 2025 | 3.49m | 0.51% |
| Liontrust Investment Partners LLPas of 30 Sep 2025 | 1.34m | 0.20% |
| Warburg Invest Kapitalanlagegesellschaft MBHas of 31 May 2025 | 600.00k | 0.09% |
| American Century Investment Management, Inc.as of 08 Jan 2026 | 150.04k | 0.02% |
| Rathbones Investment Management International Ltd.as of 05 Nov 2025 | 50.15k | 0.01% |
| KW Investment Management Ltd.as of 01 Jan 2026 | 0.00 | 0.00% |
